Inflammatory cytokines and white matter microstructure in the acute phase of first-episode psychosis: A longitudinal study

Carregando...
Imagem de Miniatura
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Citação
SCHIZOPHRENIA RESEARCH, v.257, p.5-18, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: Schizophrenia-related psychosis is associated with abnormalities in white matter (WM) microstructure and structural brain dysconnectivity. However, the pathological process underlying such changes is unknown. We sought to investigate the potential association between peripheral cytokine levels and WM microstructure during the acute phase of first-episode psychosis (FEP) in a cohort of drug-naive patients.Methods: Twenty-five non-affective FEP patients and 69 healthy controls underwent MRI scanning and blood collection at study entry. After achieving clinical remission, 21 FEP were reassessed; 38 age and biological sex -matched controls also had a second assessment. We measured fractional anisotropy (FA) of selected WM regions -of-interest (ROIs) and plasma levels of four cytokines (IL-6, IL-10, IFN-& gamma;, and TNF-& alpha;).Results: At baseline (acute psychosis), the FEP group showed reduced FA relative to controls in half the examined ROIs. Within the FEP group, IL-6 levels were negatively correlated with FA values. Longitudinally, patients showed increments of FA in several ROIs affected at baseline, and such changes were associated with reductions in IL-6 levels.Conclusions: A state-dependent process involving an interplay between a pro-inflammatory cytokine and brain WM might be associated with the clinical manifestation of FEP. This association suggests a deleterious effect of IL-6 on WM tracts during the acute phase of psychosis.
Palavras-chave
Psychosis, Schizophrenia, Inflammation, Cytokines, Magnetic Resonance Imaging, Diffusion Tensor Imaging
Referências
  1. Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011
  2. Andreasen NC, 2010, BIOL PSYCHIAT, V67, P255, DOI 10.1016/j.biopsych.2009.08.040
  3. Andreasen NC, 2005, AM J PSYCHIAT, V162, P441, DOI 10.1176/appi.ajp.162.3.441
  4. Arnson Y, 2010, J AUTOIMMUN, V34, pJ258, DOI 10.1016/j.jaut.2009.12.003
  5. Asami T, 2014, PSYCHIAT RES-NEUROIM, V222, P52, DOI 10.1016/j.pscychresns.2014.02.007
  6. Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782
  7. Cai HQ, 2020, MOL PSYCHIATR, V25, P761, DOI 10.1038/s41380-018-0235-x
  8. Capuzzi E, 2017, NEUROSCI BIOBEHAV R, V77, P122, DOI 10.1016/j.neubiorev.2017.03.003
  9. Catani M, 2011, BIOL PSYCHIAT, V70, P1143, DOI 10.1016/j.biopsych.2011.06.013
  10. Charlson FJ, 2018, SCHIZOPHRENIA BULL, V44, P1195, DOI 10.1093/schbul/sby058
  11. Cloutier M, 2016, J CLIN PSYCHIAT, V77, P764, DOI 10.4088/JCP.15m10278
  12. Corsi-Zuelli F, 2021, NEUROSCI BIOBEHAV R, V125, P637, DOI 10.1016/j.neubiorev.2021.03.004
  13. Curcic-Blake B, 2015, HUM BRAIN MAPP, V36, P4859, DOI 10.1002/hbm.22955
  14. Di Biase MA, 2021, SCHIZOPHRENIA BULL, V47, P542, DOI 10.1093/schbul/sbaa134
  15. Doshi J, 2016, NEUROIMAGE, V127, P186, DOI 10.1016/j.neuroimage.2015.11.073
  16. Doshi J, 2013, ACAD RADIOL, V20, P1566, DOI 10.1016/j.acra.2013.09.010
  17. Fernandes BS, 2016, MOL PSYCHIATR, V21, P554, DOI 10.1038/mp.2015.87
  18. Field A, 2013, DISCOVERING STAT USI, V4th
  19. First M.B., 1995, STRUCTURED CLIN INTE
  20. Fitzsimmons J, 2013, CURR OPIN PSYCHIATR, V26, P172, DOI 10.1097/YCO.0b013e32835d9e6a
  21. Fraguas D, 2017, INT J NEUROPSYCHOPH, V20, P435, DOI 10.1093/ijnp/pyx015
  22. FRISTON KJ, 1995, CLIN NEUROSCI, V3, P89
  23. Fu G, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00052
  24. Gallego JA, 2018, SCHIZOPHR RES, V202, P64, DOI 10.1016/j.schres.2018.07.019
  25. Gangadin SS, 2019, CURR OPIN PSYCHIATR, V32, P164, DOI 10.1097/YCO.0000000000000498
  26. GATTAZ WF, 1992, SCHIZOPHR RES, V6, P237, DOI 10.1016/0920-9964(92)90006-Q
  27. Girgis RR, 2018, NEUROPSYCHOPHARMACOL, V43, P1317, DOI 10.1038/npp.2017.258
  28. Goldsmith DR, 2016, MOL PSYCHIATR, V21, P1696, DOI 10.1038/mp.2016.3
  29. Hawiger J, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12812
  30. James SL, 2018, LANCET, V392, P1789, DOI [10.1016/s0140-6736(18)32279-7, 10.1016/S0140-6736(18)32335-3]
  31. Jones DK, 2008, CORTEX, V44, P936, DOI 10.1016/j.cortex.2008.05.002
  32. Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081
  33. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
  34. Kelly S, 2018, MOL PSYCHIATR, V23, P1261, DOI 10.1038/mp.2017.170
  35. Kim S, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.229
  36. Kubicki M, 2014, CURR OPIN PSYCHIATR, V27, P179, DOI 10.1097/YCO.0000000000000053
  37. Kyu HH, 2018, LANCET, V392, P1859, DOI 10.1016/s0140-6736(18)32335-3
  38. Laskaris LE, 2016, BRIT J PHARMACOL, V173, P666, DOI 10.1111/bph.13364
  39. Lyall AE, 2018, MOL PSYCHIATR, V23, P701, DOI 10.1038/mp.2017.43
  40. MacCabe JH, 2008, PSYCHOL MED, V38, P1133, DOI 10.1017/S0033291707002048
  41. Mantyla T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125112
  42. Miller BJ, 2011, BIOL PSYCHIAT, V70, P663, DOI 10.1016/j.biopsych.2011.04.013
  43. Mongan D, 2020, EARLY INTERV PSYCHIA, V14, P385, DOI 10.1111/eip.12859
  44. Monji A, 2013, PROG NEURO-PSYCHOPH, V42, P115, DOI 10.1016/j.pnpbp.2011.12.002
  45. Muller N, 2018, SCHIZOPHRENIA BULL, V44, P973, DOI 10.1093/schbul/sby024
  46. Najjar S, 2015, SCHIZOPHR RES, V161, P102, DOI 10.1016/j.schres.2014.04.041
  47. Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058
  48. Orlovska-Waast S, 2019, MOL PSYCHIATR, V24, P869, DOI 10.1038/s41380-018-0220-4
  49. Ou YM, 2011, MED IMAGE ANAL, V15, P622, DOI 10.1016/j.media.2010.07.002
  50. Pasternak O., 2012, THE J
  51. Pasternak O, 2018, NEUROIMAGE, V182, P259, DOI 10.1016/j.neuroimage.2018.04.051
  52. Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055
  53. Peters BD, 2015, SCHIZOPHR RES, V161, P61, DOI 10.1016/j.schres.2014.05.021
  54. Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612
  55. Pillinger T, 2019, SCHIZOPHRENIA BULL, V45, P1120, DOI 10.1093/schbul/sby160
  56. Plaven-Sigray P., 2021, HHS PUBLIC ACCESS
  57. Pollak TA, 2018, LANCET PSYCHIAT, V5, P79, DOI 10.1016/S2215-0366(17)30293-6
  58. Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024
  59. Prasad KM, 2015, SCHIZOPHR RES, V161, P119, DOI 10.1016/j.schres.2014.09.043
  60. Roalf DR, 2015, SCHIZOPHR RES, V161, P42, DOI 10.1016/j.schres.2014.09.026
  61. Rodrigue AL, 2019, HUM BRAIN MAPP, V40, P4180, DOI 10.1002/hbm.24694
  62. Romeo B, 2018, INT J NEUROPSYCHOPH, V21, P828, DOI 10.1093/ijnp/pyy062
  63. Schmidt A, 2015, FRONT HUM NEUROSCI, V8, DOI [10.3389/fnhum.2014.00948, 10.3389/fnhum.2014.01047]
  64. Schmidt FM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121971
  65. Skelly LR, 2008, SCHIZOPHR RES, V98, P157, DOI 10.1016/j.schres.2007.10.009
  66. Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
  67. Tourjman V, 2013, SCHIZOPHR RES, V151, P43, DOI 10.1016/j.schres.2013.10.011
  68. Upthegrove R, 2014, SCHIZOPHR RES, V155, P101, DOI 10.1016/j.schres.2014.03.005
  69. van den Heuvel MP, 2014, NEUROPSYCHOL REV, V24, P32, DOI 10.1007/s11065-014-9248-7
  70. Wang AK, 2018, SCHIZOPHRENIA BULL, V44, P75, DOI 10.1093/schbul/sbx035
  71. Wang Y., 2020, SCHIZOPHR RES
  72. WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419
  73. West PK, 2019, GLIA, V67, P1821, DOI 10.1002/glia.23634
  74. Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060
  75. Yao L, 2013, PROG NEURO-PSYCHOPH, V45, P100, DOI 10.1016/j.pnpbp.2013.04.019
  76. Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027
  77. Zanetti M.V., 2017, PSYCHOL MED